Comparison of CA 15-3 and CEA in diagnosis and monitoring of breast cancer

1989 ◽  
Vol 4 (4) ◽  
pp. 207-214 ◽  
Author(s):  
F. Safi ◽  
I. Kohler ◽  
E. Röttinger ◽  
P. Suhr ◽  
H. G. Beger
Keyword(s):  
Breast Cancer ◽  
Serum Levels ◽  
Tumor Stage ◽  
Breast Cancer Patients ◽  
Curative Surgery ◽  
Benign Diseases ◽  
Breast Cancer Metastases ◽  
Normal Limits ◽  
Cancer Metastases ◽  
Tumor Associated Antigen

In order to assess the utility of the tumor-associated antigen CA15-3 in the diagnosis of breast cancer, this new tumor marker was measured pre-operatively in 1342 patients. This group comprised 509 patients with malignant disease (134 with breast cancer and 375 with other malignancies not involving the breast) and 833 patients with benign surgical diseases (95 patients with fibroadenoma of the breast, 738 with other benign diseases). The results were compared with those for carcino-embryonic antigen (CEA) in the diagnosis of breast cancer. CA15-3 was above the normal limits of 25 U/ml in 31% of the patients with breast cancer, in 22% of patients with other malignancies, and in 9% of patients with benign diseases. CEA was elevated in 26% of patients with breast cancer (> 3ng/ml). CA15-3 levels were above 50 U/ml in 13% of the breast cancer patients, in 6%) of patients with other malignancies, and in 0.2% of the patients with benign diseases. There was a good correlation between CA 15-3 level and tumor stage in breast cancer. CA 15-3 serum levels were over 50 U/ml in respectively 0%, 2%, 13%, and 73% of the patients with stages I, II, III, and IV. CA 15-3 and CEA were also determined in 671 patients who had received initial curative surgery of breast cancer, and who regularly attended our follow-up clinic. CA15-3 was found to be more sensitive than CEA in detecting recurrences of breast cancer. In the post-care period, carcinoma recurred in 205 patients. Of these 73% had CA15-3 concentrations above 25 U/ml, whereas only 50% had CEA values above 3 ng/ml (p< 0.0001). Although neither CA15-3 nor CEA are sensitive enough for the screening and diagnosis of early breast cancer, CA 15-3 is superior to CEA in the detection of breast cancer metastases.

CA 549 and SP2 in postoperative breast cancer patients. Comparison with CA 15.3, CEA and TPA

1995 ◽  
Vol 10 (2) ◽  
pp. 94-99 ◽  
Author(s):  
M. Torres ◽  
C. Pacheco ◽  
A. Valverde ◽  
A.C. Rebollo ◽  
A. Moral ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Statistical Analysis ◽  
Cancer Patients ◽  
Blood Donors ◽  
Serum Levels ◽  
Breast Cancer Patients ◽  
Benign Diseases ◽  
Ca 15.3 ◽  
Cancer Group ◽  
Breast Cancer Group

The levels of CA 549 and SP2 were measured in 430 subjects: 100 healthy blood donors, 130 patients with benign diseases and 200 postoperative breast cancer patients. In the latter group, the serum levels of CA 15.3, CEA and TPA were also measured. The Kolmogorov-Smirnov, Mann Whitney and McNemar tests were used for statistical analysis. The upper normal limits were established on the basis of the values obtained in the healthy blood donors group, the benign diseases group and R.O.C. analysis of the breast cancer group. They were: CA 549 = 13 U/ml, SP2 = 14 U/ml, CA 15.3 = 35 U/ml, CEA = 5 ng/ml and TPA = 110 U/ml. The sensitivity, specificity and accuracy in the breast cancer group were, respectively: CA 549 = 78.1%, 97.1% and 88%; SP2 = 21.9%, 90.4% and 57.5%; CEA = 66.7%, 95.2% and 81.5%; CA 15.3 = 80.2%, 98.1% and 89.5%, and TPA = 73.9%, 78.8% and 76.5%. Statistical analysis showed significant differences only between CA 15.3, the marker which gave the best results, and SP2 (p<0.001). There were no significant differences with the association of two or three tumor markers.

scholarly journals Stereotactic radiotherapy of breast cancer liver metastases

2021 ◽  
Vol 67 (3) ◽  
pp. 382-390
Author(s):  
Sergei Tkachev ◽  
Sevil Alieva ◽  
Sergey Medvedev ◽  
Aleksei Nazarenko ◽  
Denis Romanov ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Overall Survival ◽  
Liver Metastases ◽  
Cancer Patients ◽  
Stereotactic Radiotherapy ◽  
Survival Rates ◽  
Breast Cancer Patients ◽  
Breast Cancer Metastases ◽  
Cancer Metastases ◽  
Breast Cancer Liver Metastases

Stereotactic body radiation therapy currently occupies its place in the complex treatment of cancer patients with liver metastases. It is assumed that certain groups of patients with breast cancer can benefit from the use of this method, which can be converted into improved overall survival and survival rates without signs of progression of the process. Purpose of the study was to evaluate the efficacy and tolerability of stereotactic radiotherapy in patients with breast cancer metastases in the liver. We have analyzed the results of using stereotactic radiotherapy in 25 breast cancer patients with 43 liver metastases. The treatment was carried out in 3 fractions with a fraction dose of 10-15 Gy and a total dose of 30-45 Gy. Growth of the irradiated lesions was recorded only in 1 case out of 43 metastases (2,3%) and 25 (4%) patients. 1-, 3- and 5-year overall survival rates from the moment of stereotactic radiotherapy were 82,9%, 62% and 38,7%, respectively. Long-term post-radiation adverse events were observed in 8% of cases and did not have a significant effect on the quality of life and the possibility of antitumor treatment. So stereotactic radiotherapy can be recommended as a relatively safe and highly effective method of elimination of breast cancer liver metastases. Taking into account the high achieved local control, further studies on dose escalation in this group of patients are not required.  

Comparison of CA 72-4, CA 19-9 and CEA in the diagnosis and monitoring of gastric cancer

1995 ◽  
Vol 10 (2) ◽  
pp. 100-106 ◽  
Author(s):  
F. Safi ◽  
V. Kuhns ◽  
H.G. Beger
Keyword(s):  
Gastric Cancer ◽  
Malignant Disease ◽  
Normal Limit ◽  
Serum Levels ◽  
Tumor Stage ◽  
Benign Diseases ◽  
Tumor Associated Antigen ◽  
Gastric Cancer Patients ◽  
Screening And Diagnosis ◽  
Care Period

In order to assess the utility of the tumor-associated antigen CA 72-4 in the diagnosis and monitoring of gastric cancer, this tumor marker was measured preoperatively in 718 patients. This group comprised 282 patients with malignant disease (115 with gastric cancer and 167 with other malig-nancies not involving the stomach) and 476 patients with benign surgical diseases. The results were compared with those for carcinoembryonic antigen (CEA) and the tumor-associated antigen CA 19-9. CA 72-4 was above the normal limit of 2.5 U/ml in 61% of the patients with gastric cancer, in 35% of the patients with other malignancies, and in 7% of the patients with benign diseases. CEA and CA 19-9 were elevated in 37% of the patients with gastric cancer (>3 ng/mlfor CEA and >37 U/ml for CA 19-9). CA 72-4 levels were above 10 U/ml in 26% of the gastric cancer patients, in 15% of patients with other malignancies, and in 0.4% of the patients with benign diseases. There was a good correlation between CA 72-4 level and tumor stage in gastric cancer. CA 72-4 serum levels were over 2.5 U/ml in 31%, 48%, 68% and 88% of patients with stage I, II, III and IV disease, respectively. CA 72-4 was found to be more sensitive than CEA and CA 19-9 in detecting recurrences of gastric cancer. In the postoperative-care period, carcinoma recurred in 29 patients. Of these 93% had CA 72-4 concentrations above 2.5 U/ml, whereas only 59% and 35% had pathological CEA and CA 19-9 serum levels (p<0.002, p<0.0001). Although neither CA 72-4 nor CEA and CA 19-9 are sensitive enough for screening and diagnosis of early gastric cancer, CA 72-4 is superior to CEA and CA 19-9 in the detection of gastric cancer recurrences.

scholarly journals Metastatic Heterogeneity of Breast Cancer: Companion and Theranostic Approach in Nuclear Medicine

Cancers ◽  
2020 ◽  
Vol 12 (4) ◽  
pp. 821 ◽  
Author(s):  
Christopher Montemagno ◽  
Gilles Pagès
Keyword(s):  
Breast Cancer ◽  
Nuclear Medicine ◽  
Cancer Patients ◽  
Current Knowledge ◽  
Metastatic Breast ◽  
Breast Cancer Patients ◽  
Future Directions ◽  
Breast Cancer Metastases ◽  
Cancer Metastases ◽  
Common Malignancy

Breast cancer is the most common malignancy in women throughout the world. Metastatic dissemination to vital organs is the leading cause of breast cancer-related deaths. The treatment of metastases is mainly based on the primary tumor characteristics. However, breast cancer metastases exhibit high heterogeneity leading to different prognosis and therapeutic responses. Getting access to phenotype of metastases would allow better management of patients. The advent of theranostics in nuclear medicine has opened new opportunities for the diagnosis and treatment of cancer patients. The aim of this review is to provide an overview of current knowledge and future directions in nuclear medicine for therapeutic management of metastatic breast cancer patients.

scholarly journals Correlation Between Bone Scintigraphy and Tumor Markers in Patients with Breast Carcinoma

2006 ◽  
Vol 6 (1) ◽  
pp. 75-77 ◽  
Author(s):  
Amela Begić ◽  
Elma Kučukalić-Selimović ◽  
Nermina Obralić ◽  
Osman Durić ◽  
Nadir Lačević ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Bone Metastases ◽  
Bone Scintigraphy ◽  
Tumor Markers ◽  
Serum Levels ◽  
Whole Body ◽  
Chi Square ◽  
Breast Cancer Metastases ◽  
Cancer Early Detection ◽  
Cancer Metastases

A characteristic feature of many cancer types is their ability to metastasise to the skeleton. Bone is the most common site of metastatic invasion, after hematogenous spreading of breast cancer. Early detection of bone metastases is mandatory in the evaluation and management of these patients. Bone scintigraphy is commonly performed in detection and evaluation bone metastases. Tumor markers are present in healthy individuals as well as in patients with malignant diseases but in different concentration. Aim of study was to correlate serum levels of tumor marker Ca (15-3), CEA and presence of bone metastases detected by bone scintigraphy. Study included 25 patients with breast cancer, previously surgically treated. All patients underwent whole body scintigraphy. Ca (15-3) and CEA was measured by radioimmunoassay. Presence, number of bone metastases were correlated with Ca (15-3) and CEA levels. Median age of patients included in study was 50 varying from 30 to 67. Bone scintigraphy revealed bone metastases in 16 (64%) patients. A weak correlation was found between number of metastases and level of Ca (15-3) (r=0.139, p=0.254). Significant differences in Ca (15-3) level was found in patient with metastases compared to patients without metastases (chi square 0, p=1.0). Good correlation was found between number of metastases and serum level of CEA. Correlation between level of two tumor markers Ca (15-3) and CEA was a weak (r = 0.096 , p=0.323). Bone scintigraphy is a sensitive diagnostic toll for detecting breast cancer metastases to bone. Serum levels of tumor markes in isolation can not give complete accuracy about bone metastases.

scholarly journals The Benefit of Baseline Staging–Risk Assessment of Distant Breast Cancer Metastases by Tumor Stage

2016 ◽  
Vol 36 (9) ◽  
pp. 4909-4914 ◽  
Author(s):  
NELMIN RIOS ◽  
NINA ADASKINA ◽  
CORNELIA FRÖMKE ◽  
FRANK PAPENDORF ◽  
CORDULA SCHIPPERT ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Risk Assessment ◽  
Tumor Stage ◽  
Breast Cancer Metastases ◽  
Cancer Metastases ◽  
Baseline Staging

Liver Surgery for Breast Cancer Metastases

2009 ◽  
Vol 69 (05) ◽  
Author(s):  
EC Schest ◽  
H Cerwenka ◽  
A El-Shabrawi ◽  
H Bacher ◽  
HJ Mischinger
Keyword(s):  
Breast Cancer ◽  
Liver Surgery ◽  
Breast Cancer Metastases ◽  
Cancer Metastases

Deprivation of the vitamin D receptor (VDR) fuels breast cancer metastases to bone

2019 ◽  
Author(s):  
K Horas ◽  
M Abraham ◽  
F Jakob ◽  
R Ebert ◽  
G Maier ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Vitamin D ◽  
Vitamin D Receptor ◽  
Breast Cancer Metastases ◽  
Cancer Metastases

Olfactomedin-like 2A, 2B and 3 are differentially expressed in breast cancer metastases.

2019 ◽  
Author(s):  
Shahan Mamoor
Keyword(s):  
Breast Cancer ◽  
Genetically Engineered ◽  
Differentially Expressed ◽  
Genetically Engineered Mouse Models ◽  
Breast Cancer Metastases ◽  
Multiple Datasets ◽  
Cancer Metastases ◽  
Distant Organ ◽  
Metastatic Process ◽  
Differential Gene

Differential gene expression analysis of multiple datasets, in mice and in men revealed that transcripts of the olfactomedin-like family are differentially expressed in metastases, both in patients with breast cancer and in genetically engineered mouse models of breast cancer. The expression of olfactomedin-like genes was perturbed in metastases to the bone, brain and the lung, suggesting that these molecules function in the metastatic process rather than having tissue-specific associations with the site of dissemination. The olfactomedin-like family may play a role in the progression of breast cancer from frank tumor to colonization of distant organ sites.

Sign in / Sign up

Export Citation Format

Share Document